Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).

作者
Alexander Starodub,D. Ross Camidge,Ronald J Scheff,Sajeve Samuel Thomas,Michael J. Guarino,Gregory A. Masters,Kevin M. Kalinsky,Leena Gandhi,Aditya Bardia,Wells A. Messersmith,Allyson J. Ocean,Pius P. Maliakal,Robert M. Sharkey,Francois E. Wilhelm,David M. Goldenberg,Rebecca Suk Heist
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:34 (15_suppl): 8559-8559 被引量:8
标识
DOI:10.1200/jco.2016.34.15_suppl.8559
摘要

8559 Background: Sacituzumab govitecan (IMMU-132) is a novel ADC comprising SN-38, the active metabolite of the topoisomerase inhibitor, irinotecan, conjugated to an anti-Trop-2 humanized antibody. Its uniquely very high drug:antibody ratio of 7.6 allows delivering up to 136-fold more SN-38 than its parent drug, irinotecan, in a human cancer xenograft. The mAb and ADC are immunotherapeutic in vitro (ADCC). Expression of Trop-2 is increased in most epithelial cancers (>80%), including SCLC. Therefore, the efficacy and safety of this new ADC is being examined in previously treated mSCLC. Methods: A Phase I/II clinical trial (ClinicalTrials.gov, NCT01631552) is enrolling mSCLC pts, administering IMMU-132 on days 1 and 8 of 21-day treatment cycles. Treatment continues based on tolerance or until progression, with safety and response assessments (RECIST 1.1) made every week and at 8-12 weeks, respectively. No prophylactic diarrhea or G-CSF medication is given. Results: Thirty-one mSCLC pts were enrolled by 11/19/15. Twenty-eight pts are assessable [median age 63 yrs, 10 M/18 F, ECOG 0 (N=5)/1 (N=23)], with a median of 2.5 (range: 1-5) prior chemotherapies. Pts were given IMMU-132 doses at 8 mg/kg (N=15) or 10 mg/kg (N=13). All pts had previous treatment with platinum-based therapy and etoposide, and 9 had received topotecan. Responses are shown in the Table. Among reported adverse events so far (n=27), grade 3+ drug-related toxicities above 5% incidence are neutropenia (33%) and diarrhea (7%). No pt developed antibodies (by ELISA) to the antibody or drug. Conclusions: Encouraging objective responses with a good therapeutic index support further study of IMMU-132 in pts with previously treated mSCLC. Clinical trial information: NCT01631552.IMMU-132 Dosage Objective Response Rate (PR) including confirmed and unconfirmed data Clinical benefit (PR+ SD > 4 Months Median Progression-Free Survival (Months) (% Maturity) Median Overall Survival (Months) (% Maturity) 8 mg/kg (N=15) 15% 31% 2.0 (87%) 8.1 (60%) 10 mg/kg (N=13) 31% 54% 4.6 (77%) 8.3 (46%)

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
不吃鱼完成签到,获得积分10
刚刚
oysu完成签到 ,获得积分10
刚刚
刚刚
xzh完成签到,获得积分10
刚刚
Amazing0604完成签到,获得积分20
刚刚
Rita不秃头完成签到,获得积分10
1秒前
江小雪完成签到,获得积分10
1秒前
1秒前
DJ完成签到,获得积分10
1秒前
HwanPen完成签到,获得积分10
1秒前
2秒前
2秒前
砂糖橘发布了新的文献求助10
2秒前
halo发布了新的文献求助10
2秒前
霸气的念云完成签到,获得积分10
2秒前
2秒前
ding的应助被N1koooooo采纳,获得10
3秒前
萨克斯发布了新的文献求助10
3秒前
土多多完成签到,获得积分10
3秒前
wanci的应助被hhf123采纳,获得10
3秒前
十一发布了新的文献求助10
3秒前
千寻一醉发布了新的文献求助10
3秒前
wu完成签到,获得积分10
3秒前
aaaiii完成签到,获得积分10
3秒前
4秒前
4秒前
chishuiwen发布了新的文献求助10
5秒前
123完成签到,获得积分10
5秒前
zzj发布了新的文献求助10
6秒前
冰雪物语完成签到,获得积分10
6秒前
6秒前
Tiffan完成签到,获得积分10
6秒前
laoying发布了新的文献求助10
6秒前
CodeCraft的应助被浆糊朋友采纳,获得10
6秒前
其实完成签到,获得积分10
6秒前
6秒前
6秒前
6秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159929
求助须知:如何正确求助?哪些是违规求助? 9555266
关于积分的说明 21726335
捐赠科研通 7749807
什么是DOI,文献DOI怎么找? 3427310
关于科研通互助平台的介绍 2552391
邀请新用户注册赠送积分活动 2471654